Thick Blood and a High IgM: Waldenstrom Macroglobulinaemia

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

A protein result flagged high on a panel ordered for something else entirely. Then, months later, a headache that will not settle, a nosebleed, vision going soft by evening. Three complaints, three tidy explanations, and not one of them is the protein. The number lived in one chart and the symptoms arrived in another, read by different people months apart, so nothing ever joined them. Keeping one abnormal protein and every flag it distorts in a single case is what Healz is for.

Category
Health Insights
Date
Reading time
11 min
Share

Waldenstrom macroglobulinaemia is the disease behind that pairing. What follows is what the diagnosis requires, how one protein harms in two ways, and why a high IgM alone is not treated.

Thick Blood and a High IgM: Waldenstrom Macroglobulinaemia

What the diagnosis actually requires

Two findings have to be present at once. The first is in the marrow: the disorder underlying Waldenstrom macroglobulinaemia is a lymphoplasmacytic lymphoma, "defined by bone marrow (BM) infiltration by small lymphocytes, lymphoplasmacytoid cells and plasma cells" (Askari et al., Journal of Blood Medicine, 2021). The second is in the blood: per the NCI PDQ health professional summary, lymphoplasmacytic lymphoma "is usually associated with a monoclonal serum paraprotein of immunoglobulin M (IgM) type".

Neither half is the diagnosis alone, and that is also what separates this from the better-known monoclonal protein diseases. It is classed among the indolent B-cell lymphomas rather than the plasma cell neoplasms, which is where the NCI PDQ health professional summaries place it; the infiltrate is lymphoplasmacytic rather than purely plasmacytic, and lytic bone lesions are absent rather than present (Bhatt et al., Maedica, 2014). The CRAB pattern of calcium, kidney, anaemia and bone damage covered in our piece on the vague symptoms of multiple myeloma is not the picture here, and a single plasma cell lesion with a clean marrow is a third diagnosis again, covered in our piece on solitary plasmacytoma.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

IgM monoclonal gammopathy of undetermined significance and smouldering disease both come before it, and the border between them is not a number. The eleventh International Workshop consensus panel on diagnostic criteria reaffirmed that "arbitrary values for laboratory parameters such as minimal IgM level or bone marrow infiltration should not be used to distinguish Waldenstrom's macroglobulinemia from IgM MGUS" (IWWM-11 consensus panel 4, Seminars in Hematology, 2023).

The two mutations that moved into the workup

The MYD88 L265P mutation is "highly characteristic of WM (> 90% of the patients)", WM being how the papers abbreviate the disease, with reported detection rates spread from 71% to 100% depending on method, and CXCR4 mutations "are present in 30-40% of WM patients" (Askari et al., 2021). Per the NCI PDQ health professional summary, most patients carry the MYD88 variant, and some pathologists consider it indicative of the disease.

These are not footnotes. The eleventh International Workshop panel on symptomatic, treatment-naive patients states that "whenever possible, the mutational status of MYD88 and CXCR4 should be determined before treatment initiation, as alterations in these 2 genes predict sensitivity towards cBTKi activity", meaning the covalent Bruton tyrosine kinase inhibitors (IWWM-11 consensus panel 1, Seminars in Hematology, 2023). Both sit in the baseline workup beside the marrow biopsy (Cingam and Sidana, Blood and Lymphatic Cancer, 2022), so a molecular result arriving weeks after the pathology is part of the answer.

Two ways one disease does harm

The harm arrives by two mechanisms, unrelated except in sharing a cause.

The first is crowding, which behaves like other marrow diseases. "Cytopenias are caused by the malignant infiltration of the bone marrow by lymphoplasmacytic cells", and "symptomatic anemia is the most common manifestation" of the disease (Cingam and Sidana, 2022).

The second has nothing to do with the marrow. It is the IgM molecule itself, a very large antibody, doing things in the circulation that no cell count records. Each of the syndromes that follow gets attributed to something else first:

  • Hyperviscosity. Thickened plasma, with headache, dizziness, nosebleeds and blurred vision.
  • Peripheral neuropathy, in a subset associated with antibodies against myelin-associated glycoprotein.
  • Cryoglobulinaemia. Type I is the form usually seen here, and "cryoglobulins can deposit in medium and large-sized blood vessels" (Askari et al., 2021).
  • Cold agglutinin haemolysis, where "IgM acts as an autoantibody against red blood cell antigens, producing Hemolytic anemia" (Askari et al., 2021).
  • Amyloidosis from deposition of the monoclonal protein, presenting as nephrotic syndrome, neuropathy, cardiomyopathy or liver dysfunction (Cingam and Sidana, 2022).

The neurologist sees the neuropathy, the ophthalmologist the retina, the haematologist the counts. The protein is what they share, and usually what nobody is holding.

Why the eye is part of the assessment

Hyperviscosity is the syndrome that can turn urgent, and it has a sign that does not depend on how the patient describes the headache. "The predominant symptoms of HVS are mucocutaneous bleeding, ophthalmologic, and neurologic", HVS being hyperviscosity syndrome, with epistaxis a common presenting symptom and neurological features that "can range from relatively mild headache and lightheadedness to seizures and coma". The eye findings run from blurred or double vision to retinal haemorrhage and central retinal vein occlusion, which can cause irreversible vision loss (Weaver et al., Frontiers in Oncology, 2020).

So the fundus gets looked at rather than asked about. "A fundoscopic examination should be performed in any patient with suspected HVS", and the characteristic finding is "retinal vein dilation with tortuous 'sausage link' appearance on retinal veins" (Weaver et al., 2020). The published workup lists it for anyone in whom hyperviscosity is suspected or whose IgM is at least 3.0 g/dL (Cingam and Sidana, 2022). Measured viscosity backs it up: per the NCI PDQ health professional summary, above a serum viscosity four times that of water the patient may have symptoms of hyperviscosity.

What the laboratory sees, and what the protein does to it

The tests are specific: serum protein electrophoresis with immunofixation, serum free light chains, urine electrophoresis, quantitative immunoglobulins, serum viscosity, a marrow biopsy with morphology and flow, MYD88 and CXCR4 analysis, cryoglobulins and Coombs testing where indicated, and imaging for nodes and organ enlargement (Cingam and Sidana, 2022). The NCI PDQ health professional summary adds a check for hepatitis C virus infection.

Then the part that catches people out. A protein that large interferes with the measurement of other things:

  • Rouleaux. "Blood smear shows stacks or aggregations of red blood cells (rouleaux phenomenon) due to paraproteinemia" (Askari et al., 2021).
  • An artefactually low sodium. The effect is platform-dependent: on one analyser, "macroglobulins occupy plasma volume during dilution, causing underestimation of sodium and chloride" through the electrolyte exclusion effect; on another the same paper attributes it to precipitation instead. Pseudohyponatraemia attributable to IgM has been reported in single cases (Wang et al., Biochemia Medica, 2026).
  • A temperature-dependent IgM result. Cryoglobulins or cold agglutinins can give a falsely low IgM unless the sample is kept warm (Cingam and Sidana, 2022).

Why a high IgM by itself is not treated

Treatment answers symptoms and end-organ effects, not a laboratory value. Therapy "is only indicated in patients symptomatic from adenopathy, organomegaly, neuropathy, hyperviscosity, cryoglobulinemia, cold agglutinin disease, cytopenias (Hb<10 gm/dl, platelets <50 x 103/microL) or amyloidosis" (Cingam and Sidana, 2022). Per the NCI PDQ health professional summary, asymptomatic patients can be monitored for progression without immediate chemotherapy, and the eleventh International Workshop panel holds that watchful waiting "remains the gold standard for asymptomatic patients without critically elevated IgM or compromised hematopoietic function" (IWWM-11 consensus panel 1, 2023).

When hyperviscosity is symptomatic, plasmapheresis is the immediate measure. Per the NCI PDQ health professional summary it is useful for temporary acute problems such as retinopathy, heart failure and central nervous system dysfunction, and it "rapidly reverses the clinical symptoms of hyperviscosity" (Weaver et al., 2020). It is a bridge used while systemic therapy gets going (Cingam and Sidana, 2022): it removes protein and leaves the marrow infiltrate untouched.

The drug classes, named without endorsing any of them, are the Bruton tyrosine kinase inhibitors, the anti-CD20 antibody rituximab, alkylating agents, proteasome inhibitors and nucleoside analogues (NCI PDQ health professional summary). One sequencing detail belongs in a patient's own vocabulary: the IgM flare. "Initial rituximab therapy is associated with an increase in serum IgM concentrations in 30-70% of patients", peaking at a mean of four weeks, so the protein rises before it falls (Weaver et al., 2020). That review recommends adding rituximab only when serum IgM is below 4,000 mg/dL, and plasma exchange first at an IgM of 4,000 mg/dL or above, or a serum viscosity above 3.5 centipoise. Per the NCI PDQ health professional summary, the rise can be avoided by giving an alkylating agent or a proteasome inhibitor alongside it.

How Healz reads one protein that distorts everything at once

One abnormal protein can bend the blood work and produce the symptoms at the same time, so the electrophoresis result, the eye findings and the counts only mean something read as one picture rather than as four separate flags. Healz keeps everything in one place, one chat rather than ten apps, so the paraprotein, the quantitative IgM, the haemoglobin and the fundus report sit in the same case.

Healz is equipped with Frontier AI, so the whole case gets worked rather than its newest page. As a blood test ai analyzer and a cancer ai that will read pathology report wording as written, it reads the immunofixation line against the counts.

Healz is equipped with root-cause technology, so it does not stop at the first label and asks what a rushed appointment skips: whether MYD88 and CXCR4 were tested, whether the fundus was examined, whether a low sodium beside a high total protein was questioned. It cross-checks the case against more than a million rare cases, so a presentation that does not quite fit stays open.

Healz's memory pulls the medical facts out of every upload, keeps abnormal values up front, dates each finding and connects them across months, so an IgM from eighteen months ago sits beside today's rather than in a different portal. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

What is Waldenstrom macroglobulinaemia?

It is a lymphoplasmacytic lymphoma in the bone marrow together with a monoclonal IgM protein in the blood, and the pairing is the definition rather than either half alone. Per the NCI PDQ health professional summary, the lymphoma is usually associated with a monoclonal serum paraprotein of IgM type.

Does a high IgM level mean I need treatment?

Not by itself. Therapy is indicated for symptoms and organ effects: hyperviscosity, neuropathy, cryoglobulinaemia, cold agglutinin disease, enlarged nodes or organs, low blood counts or amyloidosis (Cingam and Sidana, 2022). Per the NCI PDQ health professional summary, asymptomatic patients can be monitored for progression without immediate chemotherapy, and the eleventh International Workshop panel calls watchful waiting the standard where IgM is not critically elevated.

What does hyperviscosity feel like?

The usual pattern is mucocutaneous bleeding, eye symptoms and neurological symptoms: nosebleeds, blurred or double vision, headache and lightheadedness, and at the severe end seizures or coma (Weaver et al., 2020). It is also visible, since a fundus examination shows dilated, tortuous retinal veins, which is why that review recommends it in suspected hyperviscosity.

Is Waldenstrom macroglobulinaemia the same as multiple myeloma?

No. The marrow infiltrate is lymphoplasmacytic rather than purely plasmacytic, lytic bone lesions are absent rather than present, and the immunophenotype differs (Bhatt et al., Maedica, 2014), though that paper warns all three have limitations. The protein class alone does not separate them, because a myeloma can also secrete IgM, which is why morphology, immunophenotype and mutation testing are used.

A number flagged on one panel and three symptoms that arrived separately are not four problems. They can be one protein, and seeing that means reading the electrophoresis, the eye and the counts as a single case.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health